Program
Comparator 1
Its studies are mostly in Influenza, Human, led by GlaxoSmithKline.
Furthest: phase 2, since Aug 6, 20252 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 20 open or running | phase 2since Aug 6, 2025 | Aug 6, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 6, 2025First study: phase 2 study in Influenza, HumanFirst studyNCT07121192 · 776 enrolled · United States
- Oct 1, 2025Phase 2 study in Influenza, HumanNCT07204964 · 971 enrolled · United States, Belgium
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07204964Influenza, Human · United States, Belgium | 2 | Completed | Aug 24, 2026 | 971 |
| NCT07121192Influenza, Human · United States | 2 | Completed | May 11, 2026 | 776 |
How it is read
Names in the registry
- “Comparator 1”, 2 entries
Conditions, from the studies’ own filings
- Influenza, Human, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.